Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zabimmune
- Development stage
- Preclinical
- Lead developer
- IngeneOx Therapeutics
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Zabimmune (also known as ZABVAX) is a vaccine enhancer being developed by IngeneOx Therapeutics for the treatment and prevention of infectious diseases. The agent is a product of the company's Z-platform, which focuses on the biology of Z-DNA and Z-RNA—left-handed helical forms of nucleic acids that serve as biological switches for the innate immune system. Zabimmune is designed to act as a potent adjuvant by leveraging these non-canonical nucleic acid structures to stimulate a robust and targeted immune response, thereby increasing the efficacy of vaccines. As of early 2023, the program is in the IND-enabling stage of development.
- Other names
- ZABVAX
Beyond the preview
Go deeper on Zabimmune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zabimmune.